Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.
Now approved in the EU. Click here for full summary of product characteristics.
Waylivra is not approved for any use and is not commercially available in the United States or other markets outside the European Union.
Our Commitment
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Our Programs
Cardiometabolic Lipid Disorders
These disorders are complex, with a multitude of risk factors related to many diseases, rare and relatively common, including pancreatitis, diabetes, liver disease, and multiple forms of cardiovascular disease.
Hereditary Transthyretin (TTR) Amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
News
October 22, 2019
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
October 07, 2019
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
September 23, 2019
Akcea Announces CEO Transition and Elects Two New Board Members
Learning about hereditary transthyretin (TTR) amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
Visit hattrchangethecourse.comLearning about familial chylomicronemia syndrome (FCS)
FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitis
Visit FCSFocus.com
